A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2017-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1 study of TAS-114 in combination with S-1 in patients with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taiho Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Life expectancy of at least 3 months

• Histological or cytological documentation of advanced solid tumors

• ECOG Performance Status of ≤ 1 (ECOG: Eastern Cooperative Oncology Group)

• Adequate bone marrow, liver and renal function

• Women of childbearing potential and men must agree to use adequate contraception